AOA Dx announces that it has signed an exclusive option agreement with Prof. Uri Saragovi providing exclusivity to develop and commercialize new cancer diagnostic technology.  Ovarian cancer is the most lethal gynecologic cancer and the third cause of death in women. Tumors are classified based on cell type and further subdivided into benign, borderline and malignant (carcinomas), according to the aggressiveness. High Grade Serous Ovarian Cancer (HGSOC) is the most malignant and is labelled “the silent killer”. Symptoms are vague and easily confounded with other conditions. More than 70% of patients present to the clinic at advanced stages of disease, when surgical and therapeutic treatments become ineffective at extending life-span.

Over the past decade, Prof. Uri Saragovi and his team have done research on gangliosides, a family of >40 different sialic acid-containing glycosphingolips. Certain gangliosides are excellent tumor-markers. The stability, invariant and non-mutating characteristics of tumor-gangliosides make them promising diagnostic biomarkers. The novel technology provides an accurate diagnosis by measuring tumor-gangliosides in a small blood volume.

This milestone is a major move for AOA Dx on its mission to improve cancer diagnosis and treatment in the field of women’s health.

”Prof. Uri Saragovi and his talented team have worked tirelessly for several years to identify a sensitive and specific biomarker for early-stage cancer diagnosis. We are proud to support this research and now begin the regulatory and commercial journey to bring it to market. There is an urgent need to accurately diagnose women earlier to give them a fighting chance at survival,” says Oriana Papin-Zoghbi, CEO at AOA Dx.

“We are proud to work with AOA Dx to help bring our research to market. The AOA Dx team has significant experience in commercializing diagnostic tests and creating market entry strategies. We look forward to an exciting partnership that will help patients,” says Prof. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University.

About AOA Dx Inc.
AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at www.aoadx.com.

Contact
Corporate Communications
info@aoadx.com